AEON Biopharma, Inc. (AEON) is a publicly traded Healthcare sector company. As of May 21, 2026, AEON trades at $0.86 with a market cap of $22.49M and a P/E ratio of -0.22. AEON moved +0.91% today. Year to date, AEON is -23.64%; over the trailing twelve months it is +69.63%. Its 52-week range spans $0.38 to $115.57. Rallies surfaces AEON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in AEON news today?
AEON Biopharma Gains FDA Support and Slashes Debt Over 90% With $6M PIPE: AEON Biopharma’s FDA Type 2a meeting endorsed its analytical similarity strategy for ABP-450 under the 351(k) pathway, guiding completion of its analytical comparability package in 2026. The company cut its debt by over 90% through a $6 million PIPE financing and convertible note exchange and holds $6.2 million in cash.
FISCHER JOST bought 60.00K (~$29.25K) on May 21, 2025.
FISCHER JOST bought 60.00K (~$30.36K) on May 20, 2025.
FISCHER JOST bought 50.00K (~$24.94K) on May 19, 2025.
AEON Analyst Consensus
AEON analyst coverage data. Average price target: $0.00.
Common questions about AEON
What changed in AEON news today?
AEON Biopharma Gains FDA Support and Slashes Debt Over 90% With $6M PIPE: AEON Biopharma’s FDA Type 2a meeting endorsed its analytical similarity strategy for ABP-450 under the 351(k) pathway, guiding completion of its analytical comparability package in 2026. The company cut its debt by over 90% through a $6 million PIPE financing and convertible note exchange and holds $6.2 million in cash.
Does Rallies summarize AEON news?
Yes. Rallies summarizes AEON news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is AEON research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AEON. It does not provide personalized investment advice.
